Malignant Pleural Mesothelioma Emerging and Marketed Drugs Assessment (2023 Updates) | Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Treatment Outlook, Competitive Landscape, and Key Companies

Delveinsight Business Research LLP

As per DelveInsight, the Malignant Pleural Mesothelioma market is anticipated to evolve immensely in the coming years, owing to the rise in healthcare spending worldwide and the launch of emerging therapies in the market. The ongoing research and development in the therapeutics segment are also anticipated to transform the treatment dynamic and market outlook.

Currently, some of the major pharma and biotech giants, such as AstraZeneca, Targovax, PharmaMar, Polaris Pharmaceuticals, and others, are involved in drug development activities for Malignant Pleural Mesothelioma.

“Malignant Pleural Mesothelioma Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Malignant Pleural Mesothelioma Market. 

The Malignant Pleural Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Malignant Pleural Mesothelioma Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights into the emerging therapies for the treatment of Malignant Pleural Mesothelioma and the aggregate therapies developed by major pharma companies.

• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Malignant Pleural Mesothelioma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) 

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Route of Administration

Malignant Pleural Mesothelioma (MPM) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravitreal

• Subretinal

• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Mechanism of Action of the Emerging Pipeline Therapies

• Interleukin-2 replacement

• Peroxidase inhibitors

• Immunologic cytotoxicity

• CBLB protein expression inhibitor

• Gene transference

• Immunologic cytotoxicity

• TRAIL receptor 2 agonist

• Programmed cell death-1 receptor antagonist

• Antibody-dependent cell cytotoxicity

Learn How the Ongoing Clinical & Commercial Activities will Affect the Malignant Pleural Mesothelioma Therapeutic Segment @

https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight

Malignant Pleural Mesothelioma Therapeutics Landscape

Several major pharma and biotech giants are developing therapies for Malignant pleural mesothelioma. Currently, MolMed is leading the therapeutics market with its Malignant pleural mesothelioma drug candidates in the most advanced stage of clinical development.

Leading Companies in the Malignant Pleural Mesothelioma Therapeutics Market Include:

ACADIA Pharmaceuticals, Aduro Biotech, Inc, AGC Biologics S.p.A, AstraZeneca, Atara Biotherapeutics, Bristol-Myers Squibb, Hoffmann-La Roche, Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceuticals, Lurbinectedin: PharmaMar, Merck Sharp & Dohme Corp., Amphera BV,  MolMed, Momotaro-Gene, Novartis, Novotech (Australia) Pty Limited, PharmaMar, Polaris Pharmaceuticals, RS Oncology, Sanofi, Sellas Life Sciences Group, Targovax, TCR2 Therapeutics, Ys Therapeutics, and many others.

Malignant Pleural Mesothelioma Emerging and Marketed Drugs Covered in the Report Include:

• ATA2271: Atara Biotherapeutics

• Galinpepimut-S (Vaccine): Sellas Life Sciences Group

• IMFINZI: AstraZeneca

• Lurbinectedin: PharmaMar

• MesoPher: Amphera BV

• MTG201 + nivolumab: Momotaro-Gene

• NGR-TNF: MolMed

• ONCOS-102: Targovax

• Pegargiminase: Polaris Pharmaceuticals

• Pembrolizumab: Merck & Co

• RSO-021: RS Oncology

• SAR-444245: Sanofi

• TC-210: TCR2 Therapeutics

• TECENTRIQ Plus AVASTIN: Hoffmann-La Roche

• YS110: Ys Therapeutics

• ZEPZELCA (lurbinectedin): PharmaMar

• NovoTTF-100L System in Combination with Chemotherapy: NovoCure

• OPDIVO (nivolumab): Bristol Myers Squibb/Ono Pharmaceutical

• Ipilimumab + nivolumab: Bristol Myers Squibb

• KEYTRUDA: Merck Sharp & Dohme

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Malignant Pleural Mesothelioma Current Treatment Patterns

4. Malignant Pleural Mesothelioma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Malignant Pleural Mesothelioma Late Stage Products (Phase-III)

7. Malignant Pleural Mesothelioma Mid-Stage Products (Phase-II)

8. Malignant Pleural Mesothelioma Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Malignant Pleural Mesothelioma Discontinued Products

13. Malignant Pleural Mesothelioma Product Profiles

14. Key Companies in the Malignant Pleural Mesothelioma Market

15. Key Products in the Malignant Pleural Mesothelioma Therapeutics Segment

16. Dormant and Discontinued Products

17. Malignant Pleural Mesothelioma Unmet Needs

18. Malignant Pleural Mesothelioma Future Perspectives

19. Malignant Pleural Mesothelioma Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @ 

https://www.delveinsight.com/sample-request/malignant-pleural-mesothelioma-mpm-pipeline-insight

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/